Oncology Corporate Profile
Ohr Pharmaceutical, Inc. is a pharmaceutical company dedicated to the development of first-in-class drugs for under-served therapeutic needs. Ohr is focused on the development of novel pharmaceuticals for the treatment of serious and unmet medical needs. Our lead product is Squalamine eye drops for the treatment of the wet form of age-related macular degeneration (wet AMD) with a potential for expansion into other indications such as diabetic macular edema (DME) and retinal vein occlusions (RVO). Wet-AMD is a leading cause of vision loss and blindness in the elderly, affecting over 1.75 million patients in the United States alone. Squalamine is currently being tested in a Phase 2 clinical trial in patients with wet AMD and may offer an alternative to individuals who wish to reduce or eliminate intravitreal injections that are required with currently available treatments. Our second product is OHR/AVR 118 for the treatment of Cancer Cachexia. Cancer Cachexia, or wasting syndrome, is characterized by symptoms of loss of appetite and body weight, fatigue, and loss of muscle mass. It is a debilitating condition that affects many late-stage cancer patients and greatly diminishes their quality of life.
This company does not have any pipeline products
3/2/2017 02:03 pm
[GlobeNewswire] - NEW YORK, March 02, 2017-- Ohr Pharmaceutical, Inc., a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that Jason Slakter, MD, Chief Executive ...